Publications

Introduction
• Somatic genomic alterations occur frequently in melanoma
• BRAF mutations are the most clinically relevant as they predict for response to targeted therapies
• Oncogenic gene fusions are frequently identified in different cancers with an unknown incidence in melanoma
• Targeted therapies are approved for specific gene fusions in other tumor types and are now standard of care
• The aim of this retrospective study was to determine the prevalence of oncogenic fusions in metastatic or locally advanced melanoma
• Gene expression analysis across a broad group of melanomas with and without fusions was performed in order to better elucidate the functional consequences of gene fusions in this aggressive malignancy